Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients-A Retrospective Observational Study.

Siringo, Marco; Gentile, Gabriella; Caponnetto, Salvatore; Sperduti, Isabella; Santini, Daniele; Cortesi, Enrico; Gelibter, Alain Jonathan

Siringo, Marco; Gentile, Gabriella; Caponnetto, Salvatore; Sperduti, Isabella; Santini, Daniele; Cortesi, Enrico; Gelibter, Alain Jonathan.

Afiliação

Siringo M; Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Gentile G; Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, 28041 Madrid, Spain.
Caponnetto S; Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Sperduti I; Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Santini D; Department of Biostatistics Unit, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.
Cortesi E; Medical Oncology Unit A, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
Gelibter AJ; Medical Oncology Unit B, Department of Radiology, Oncology and Pathology, Policlinico Umberto I, Sapienza University of Rome, 00161 Rome, Italy.

Cancers (Basel) ; 15(13)2023 Jun 30.

Article em En | MEDLINE | ID: mdl-37444532

Palavras-chave

ALK; Alectinib; BMI; NSCLC; predictive biomarker

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google